{"doi":"10.1016/j.ymthe.2020.11.007","title":"Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals","abstract":"MazF is an Escherichia coli-derived endoribonuclease that selectively cleaves ACA sequences of mRNA prevalent in HIV. We administered a single infusion of autologous CD4 T lymphocytes modified to express a Tat-dependent MazF transgene to 10 HIV-infected individuals (six remaining on antiretroviral therapy [ART]; four undergoing treatment interruption post-infusion) in order to provide a population of HIV-resistant immune cells. In participants who remained on ART, increases in CD4 and CD8 T cell counts of ~200 cells/mm3 each occurred within 2 weeks of infusion and persisted for at least 6 months. Modified cells were detectable for several months in the blood and trafficked to gastrointestinal lymph tissue. HIV-1 Tat introduced ex vivo to the modified CD4+ T cells induced MazF expression in both pre- and post-infusion samples, and MazF expression was detected in vivo post-viral-rebound during ATI. One participant experienced mild cytokine release syndrome. In sum, this study of a single infusion of MazF-modified CD4 T lymphocytes demonstrated safety of these cells, distribution to lymph tissue and maintenance of Tat-inducible MazF endoribonuclease activity, as well as sustained elevation of blood CD4 and CD8 T cell counts. Future studies to assess effects on viremia and latent proviral reservoir are warranted. MazF is an Escherichia coli-derived endoribonuclease that selectively cleaves ACA sequences of mRNA prevalent in HIV. We administered a single infusion of autologous CD4 T lymphocytes modified to express a Tat-dependent MazF transgene to 10 HIV-infected individuals (six remaining on antiretroviral therapy [ART]; four undergoing treatment interruption post-infusion) in order to provide a population of HIV-resistant immune cells. In participants who remained on ART, increases in CD4 and CD8 T cell counts of ~200 cells/mm3 each occurred within 2 weeks of infusion and persisted for at least 6 months. Modified cells were detectable for several months in the blood and trafficked to gastrointestinal lymph tissue. HIV-1 Tat introduced ex vivo to the modified CD4+ T cells induced MazF expression in both pre- and post-infusion samples, and MazF expression was detected in vivo post-viral-rebound during ATI. One participant experienced mild cytokine release syndrome. In sum, this study of a single infusion of MazF-modified CD4 T lymphocytes demonstrated safety of these cells, distribution to lymph tissue and maintenance of Tat-inducible MazF endoribonuclease activity, as well as sustained elevation of blood CD4 and CD8 T cell counts. Future studies to assess effects on viremia and latent proviral reservoir are warranted.","journal":"Molecular Therapy","year":2020,"id":110708,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.957,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":487254,"name":"Julie K. Jadlowsky","orcid":"0009-0005-5115-1321","position":1,"is_corresponding":false},{"id":105473,"name":"Simon F. Lacey","orcid":"0000-0003-2882-1962","position":2,"is_corresponding":false},{"id":256416,"name":"Joseph A. Fraietta","orcid":"0000-0001-7900-8993","position":3,"is_corresponding":false},{"id":325455,"name":"Gabriela Plesa","orcid":"0000-0002-4279-5943","position":4,"is_corresponding":false},{"id":527597,"name":"Hideto Chono","orcid":null,"position":5,"is_corresponding":false},{"id":526743,"name":"Dong Heun Lee","orcid":"0000-0002-1860-3446","position":6,"is_corresponding":false},{"id":526744,"name":"Irina Kulikovskaya","orcid":"0000-0003-2972-5454","position":7,"is_corresponding":false},{"id":527598,"name":"Chelsie Bartoszek","orcid":null,"position":8,"is_corresponding":false},{"id":526745,"name":"Fang Chen","orcid":"0000-0003-2408-204X","position":9,"is_corresponding":false},{"id":526746,"name":"Lifeng Tian","orcid":"0000-0001-9740-5327","position":10,"is_corresponding":false},{"id":526747,"name":"Alexander J. Dimitri","orcid":"0000-0002-7337-3196","position":11,"is_corresponding":false},{"id":256649,"name":"Bruce L. Levine","orcid":"0000-0001-6971-8465","position":12,"is_corresponding":false},{"id":527599,"name":"Elizabeth Veloso","orcid":null,"position":13,"is_corresponding":false},{"id":272456,"name":"Wei‐Ting Hwang","orcid":"0000-0003-2829-2167","position":14,"is_corresponding":false},{"id":227870,"name":"Carl H. June","orcid":"0000-0003-0241-3557","position":15,"is_corresponding":false},{"id":302792,"name":"Jeffrey M. Jacobson","orcid":"0000-0001-7250-1208","position":0,"is_corresponding":true}],"reference_count":19,"raw_metadata":null,"created_at":"2026-07-18T23:13:01.914939Z","pmid":"33186691","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}